Vertex Pharmaceuticals Incorporated (VRTX) Stock
VRTX Key Statistics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
CEO: Reshma Kewalramani. Company website
VRTX — Frequently Asked Questions
What is the VRTX stock price today?
Vertex Pharmaceuticals Incorporated (VRTX) trades at $547.03, down 0.16% on the day, as of Nov 12, 2026 09:20 UTC.
What is Vertex Pharmaceuticals Incorporated's market cap?
Vertex Pharmaceuticals Incorporated has a market capitalisation of $138.65B, calculated from the live VRTX share price and shares outstanding.
What is the P/E ratio of VRTX?
VRTX trades at a trailing P/E of 35.20, from earnings per share of $15.54 over the last twelve months.
How much revenue does Vertex Pharmaceuticals Incorporated make?
Vertex Pharmaceuticals Incorporated generated revenue of $12.95B over the trailing twelve months, which puts the stock at 10.71 times sales.
What is the 52-week range for VRTX?
VRTX has traded between $406.67 and $568.67 over the past 52 weeks, and the last price is 3.8% below that high.
Is Vertex Pharmaceuticals Incorporated profitable?
Yes. Vertex Pharmaceuticals Incorporated keeps 30.70% of revenue as net income over the trailing twelve months.
What is the analyst price target for VRTX?
Wall Street analysts rate VRTX Buy, with an average price target of $580.20, 6.1% above the current price.
What sector is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Vertex Pharmaceuticals Incorporated?
Reshma Kewalramani is the chief executive of Vertex Pharmaceuticals Incorporated, which employs 6,400 people.
Where can I track VRTX in real time?
QFI Terminal shows VRTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See VRTX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open VRTX in Terminal See plans